Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.

Saved in:
Bibliographic Details
Title: Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.
Authors: Bhatt DL; Mount Sinai Heart, Icahn School of Medicine, Mount Sinai Health System, New York City, NY, USA. dlbhattmd@post.harvard.edu., Bays HE; Louisville Metabolic and Atherosclerosis Research Center, University of Louisville School of Medicine, Louisville, KY, USA., Miller M; Corporal Michael J. Crescenz VA Medical Center and Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Cain JE 3rd; Family Medicine Clinic Science, Lampasas, TX, USA., Wasilewska K; ZDROWIE Osteo-Medic, Bialystok, Poland., Andrawis NS; Manassas Clinical Research Center, Manassas, VA, USA., Parli T; 89bio Inc., San Francisco, CA, USA., Feng S; 89bio Inc., San Francisco, CA, USA., Sterling L; 89bio Inc., San Francisco, CA, USA., Tseng L; 89bio Inc., San Francisco, CA, USA., Hartsfield CL; 89bio Inc., San Francisco, CA, USA., Agollah GD; 89bio Inc., San Francisco, CA, USA., Mansbach H; 89bio Inc., San Francisco, CA, USA., Kastelein JJP; Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Corporate Authors: ENTRIGUE Principal Investigators
Source: Nature medicine [Nat Med] 2024 Jun; Vol. 30 (6), pp. 1788-1789.
Publication Type: Published Erratum
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1546-170X
DOI:10.1038/s41591-024-02890-2